State Ledger
Company profile

Acurx Pharmaceuticals, Inc. CIK 1736243

Ticker
ACXP (Nasdaq)
Industry
Pharmaceutical Preparations
Headquarters
Staten Island, NY 10305
Fiscal year end
2025 (FY)
Market Data
Close
$1.27
Change
+$0.01
Change %
0.80%
Volume
395

ACXP · trading date Oct 12, 2026 · previous close $1.26 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
-$7.97M
Total assets
$7.69M
Total liabilities
$2.42M
Stockholders' equity
$5.27M
Cash & equivalents
$7.56M
Operating income
-$8.09M
Operating cash flow
-$6.79M
Capital expenditures
—

Fiscal year 2025, via 10-K filed 2026-03-12. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
31.5%
Equity / assets
68.5%
CapEx / revenue
—
Operating cash flow / net income
0.85×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 — -$7.97M $7.69M $2.42M $5.27M
2024 — -$14.10M $3.86M $3.24M $615.1K
2023 — -$14.58M $7.71M $3.04M $4.67M
2022 — -$12.09M $9.38M $2.06M $7.32M
2021 — -$12.75M $13.25M $843.9K $12.41M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form EFFECT
2026-09-17
Financials filed via
Form 10-K
filed 2026-03-12

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
Staten Island, NY 10305
259 LIBERTY AVENUE
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:45 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to New York — Public Companies